WO2003095428A1 - Dopamine receptor modulators as antipsychotic agents - Google Patents

Dopamine receptor modulators as antipsychotic agents Download PDF

Info

Publication number
WO2003095428A1
WO2003095428A1 PCT/GB2003/001983 GB0301983W WO03095428A1 WO 2003095428 A1 WO2003095428 A1 WO 2003095428A1 GB 0301983 W GB0301983 W GB 0301983W WO 03095428 A1 WO03095428 A1 WO 03095428A1
Authority
WO
WIPO (PCT)
Prior art keywords
methyl
formula
compound
disorders
tetrahydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2003/001983
Other languages
English (en)
French (fr)
Inventor
Andrew Derrick Gribble
Ian Thomson Forbes
Andrew Lightfoot
Andrew H. Payne
David Gwyn Cooper
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Priority to AU2003227919A priority Critical patent/AU2003227919A1/en
Priority to EP03725384A priority patent/EP1503989A1/en
Priority to US10/513,919 priority patent/US20070043026A1/en
Priority to JP2004503446A priority patent/JP2005532318A/ja
Publication of WO2003095428A1 publication Critical patent/WO2003095428A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom

Definitions

  • This invention relates to novel compounds, pharmaceutical compositions containing them and their use in therapy, in particular as antipsychotic agents.
  • a and B represent the groups -(CH 2 ) n and ⁇ (CH 2 ) n -respectively;
  • R 1 represents hydrogen or C h alky!;
  • R represents hydrogen, halogen, hydroxy, cyano, nitro, hydroxyd-ealkyl, trifluoromethyl, trifluoromethoxy, C h alky!, Ci-ealkoxy, C-i-efluoroalkoxy, -(CH 2 ) p C 3 - 6 cycloalkyl, -(CH 2 ) p OC 3 - ⁇ cycloalkyl, -COC.,- 6 alkyl, -SOzCveal yl, -SOC ⁇ alkyl, -S-C ⁇ alkyl, -CO 2 C ⁇ alkyl, - CO 2 NR 7 R 8 , -SO 2 NR 7 R 8 , -(CH 2 ) P NR 7 R 8 , -(CH 2 ) p NR 7 COR 8 , optionally substituted aryl, optionally substituted heteroaryl or optionally substituted heterocyclyl;
  • R 4 represents optionally substituted aryl or optionally substituted heteroaryl
  • R 5 and R 6 each independently represent hydrogen, halogen, hydroxy, cyano, nitro, hydroxyC ⁇ alkyl, trifluoromethyl, trifluoromethoxy, C h alky!, C-i-ealkoxy, -(CH 2 ) P C 3 .
  • -S-d-ealkyl -CO 2 C ⁇ - 6 alkyl, -CO 2 NR 7 R 8 , -S0 2 NR 7 R 8 , -(CH 2 ) P NR 7 R 8 , -(CH 2 ) p NR 7 COR 8 , optionally substituted aryl, optionally substituted heteroaryl or optionally substituted heterocyclyl;
  • R 7 and R 8 each independently represent hydrogen, C ⁇ - 6 alkyl or, together with the nitrogen or other atoms to which they are attached, form an azacycloalkyl ring or an oxo- substituted azacycloalkyl ring; m and n independently represent an integer selected from 1 and 2; p independently represents an integer selected from 0, 1 , 2 and 3; and either:
  • Z represents -CR 9 R 10 X- or -XCR 9 R 10 - and X represents oxygen, sulfur, -SO- or - SO 2 , or Z represents -CONR 11 - or -NR 11 CO- and X represents -CH 2 -, oxygen, sulfur, -SO- or -SO 2 ;
  • R 9 and R 10 each independently represent hydrogen, C h alky! or fluoro
  • R 11 represents hydrogen or C h alky!; or a pharmaceutically acceptable salt or solvate thereof.
  • alkyl refers to straight or branched hydrocarbon chains containing the specified number of carbon atoms.
  • C ⁇ . 6 alkyl means a straight or branched alkyl containing at least 1 , and at most 6, carbon atoms.
  • alkyl as used herein include, but are not limited to, methyl, ethyl, n-propyl, n-butyl, n-pentyl, n- hexyl, isobutyl, isopropyl, t-butyl and 1,1-dimethylpropyl.
  • alkoxy refers to a straight or branched alkoxy group containing the specified number of carbon atoms.
  • C ⁇ alkoxy means a straight or branched alkoxy group containing at least 1, and at most 6, carbon atoms.
  • alkoxy as used herein include, but are not limited to, methoxy, ethoxy, propoxy, prop-2- oxy, butoxy, but-2-oxy, 2-methylprop-1-oxy, 2-methylprop-2-oxy, pentoxy or hexyloxy.
  • C ⁇ fluoroalkoxy refers to a straight or branched alkoxy group containing the specified number of carbon atoms wherein any of the carbon atoms may be substituted by one or more fluorine atoms.
  • cycloalkyl refers to a non-aromatic hydrocarbon ring containing the specified number of carbon atoms.
  • C 3 . 7 cycloalkyl means a non-aromatic ring containing at least three, and at most seven, ring carbon atoms.
  • Examples of "cycloalkyl” as used herein include, but are not limited to, cyclopropyl; cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl.
  • a C 6 - cycloalkyl group is preferred.
  • halogen refers to the elements fluorine, chlorine, bromine and iodine. Preferred halogens are fluorine, chlorine and bromine.
  • aryl refers to a phenyl or a naphthyl ring.
  • heteroaryl refers to a 5- or 6-membered heterocyclic aromatic ring or a fused bicyclic heteroaromatic ring system.
  • heterocyclyl refers to a 3- to 7-membered monocyclic saturated ring containing at least one heteroatom independently selected from oxygen, nitrogen and sulfur.
  • suitable heterocyclic rings include, but are not limited to, piperidine and morpholine.
  • 5- or 6-membered heterocyclic aromatic ring refers to a monocyclic unsaturated ring containing at least one heteroatom independently selected from oxygen, nitrogen and sulfur.
  • suitable 5- and 6-membered heterocyclic aromatic rings include, but are not limited to, furyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, pyridyl, triazolyl, triazinyl, pyridazyl, pyrimidinyl, pyrazolyl, isothiazolyl and isoxazolyl.
  • fused bicyclic heteroaromatic ring system refers to a ring system comprising one six-membered unsaturated ring and one 5- or 6-membered unsaturated ring fused together, the ring system containing at least one heteroatom independently selected from oxygen, nitrogen and sulfur.
  • suitable fused bicyclic heteroaromatic ring systems include, but are not limited to, indolyl, benzofuranyl, quinolyl and benzothienyl.
  • azacycloalkyl ring refers to a 4- to 7-membered monocyclic saturated ring containing one nitrogen atom.
  • suitable azacycloalkyl rings are azetidine, pyrrolidine, piperidine and azepidine.
  • oxo-substituted azacycloalkyl ring refers to an azacycloalkyl ring as defined above substituted by one oxo group.
  • suitable oxo-substituted azacycloalkyl rings include, but are not limited to, azetidinone, pyrrolidinone, piperidinone and azepidinone.
  • the term “substituted” refers to substitution with the named substituent or substituents, multiple degrees of substitution being allowed unless otherwise stated.
  • the term “solvate” refers to a complex of variable stoichiometry formed by a solute (in this invention, a compound of formula (I) or a salt thereof) and a solvent. Such solvents for the purpose of the invention may not interfere with the biological activity of the solute. Examples of suitable solvents include water, methanol, ethanol and acetic acid. Most preferably the solvent used is water and the solvate may also be referred to as a hydrate.
  • salts of formula (I) should be physiologically acceptable.
  • suitable physiologically acceptable salts will be apparent to those skilled in the art and include for example acid addition salts formed with inorganic acids e.g. hydrochloric, hydrobromic, sulfuric, nitric or phosphoric acid; and organic acids e.g. succinic, maleic, malic, mandelic, acetic, fumaric, glutamic, lactic, citric, tartaric, benzoic, benzenesulfonic, p-toluenesulfonic, methanesulfonic or naphthalenesulfonic acid.
  • Other non-physiologically acceptable salts e.g. oxalates, may be used, for example in the isolation of compounds of formula (I) and are included within the scope of this invention.
  • Certain of the compounds of formula (I) may form acid addition salts with one or more equivalents of the acid.
  • the present invention includes within its scope all possible stoichiometric and non-stoichiometric forms thereof.
  • Certain compounds of formula (I) may exist in stereoisomeric forms (e.g. they may contain one or more asymmetric carbon atoms).
  • the individual stereoisomers (enantiomers and diastereomers) and mixtures of these are included within the scope of the present invention.
  • the present invention also covers the individual isomers of the compounds represented by formula (I) as mixtures with isomers thereof in which one or more chiral centres are inverted.
  • compounds of formula (I) may exist in tautomeric forms other than that shown in the formula and these are also included within the scope of the present invention.
  • the groups R 2 , R 5 , R 6 and -Z-R 4 may be located on any position on their respective phenyl rings.
  • R 2 , R 5 and R 6 represent optionally substituted aryl, optionally substituted heteroaryl or optionally substituted heterocyclyl, and R 4 represents optionally substituted aryl or optionally substituted heteroaryl
  • the optional substituents may be selected from C ⁇ - 6 alkyl, d-ealkoxy, halogen, trifluoromethyl, trifluoromethoxy, cyano and -S-C ⁇ _ 6 alkyl.
  • R 1 represents hydrogen or C ⁇ alkyl. More preferably, R 1 represents hydrogen, methyl, ethyl, n-propyl or isopropyl. Even more preferably, R 1 represents methyl.
  • R 2 represents hydrogen, halogen, C h alky!, d-ealkoxy or did-ealkylamino. More preferably, R 2 represents hydrogen, halogen, C ⁇ alkyl, C ⁇ alkoxy or diCi- 4 alkylamino. Even more preferably, R 2 represents hydrogen, methyl, ethyl, iso-propyl, chloro, bromo, methoxy, ethoxy, isopropoxy or dimethylamino.
  • the R 2 group is located at the para-position relative to the group B i.e. a compound of formula (IA)
  • the R 2 group is located at the meta-position position relative to the group B i.e. a compound of formula (IB)
  • R 2 is preferably hydrogen, methyl, ethyl, methoxy, chloro, bromo, ethoxy, isopropoxy or dimethylamino.
  • R 3 represents hydrogen or C
  • R 4 represents phenyl, thienyl or furyl, all of which may be optionally substituted. If R 4 is optionally substituted, preferably R 4 is mono- or di-substituted. More preferably, when R 4 is phenyl, one of the optional substituents is located at the 4-position relative to the attachment of R 4 to the rest of the molecule.
  • the optional substituents for the groups R 2 , R 4 , R 5 and R 6 are selected from fluoro, chloro, bromo, methyl, ethyl, t-butyl, methoxy, trifluoromethyl, trifluoromethoxy, cyano, -S-methyl and acetyl.
  • R 5 and R 6 independently represent hydrogen, methyl, fluoro or chloro.
  • R 7 and R 8 independently represent hydrogen or C ⁇ alkyl. More preferably, R 7 and R 8 independently represent hydrogen or methyl.
  • Z represents -CR 9 R 10 X- or -X- CR 9 R 10 - wherein X represents oxygen, -NH or -NMe and R 9 and R 10 represent hydrogen or fluoro.
  • Z represents -CR R X- wherein X represents oxygen and R and R 10 both represent hydrogen i.e. -CH 2 O-.
  • the -Z-R 4 group is located either at the para-position in relation to the sulfonamide group i.e. a compound of formula (IC)
  • p represents 0.
  • m is 1 and n is 1 and the invention is a compound of formula (IE):
  • m is 2 and n is 1 and the invention is a compound of formula (IF):
  • m is 1 and n is 2 and the invention is a compound of formula (IG):
  • n 2 and the invention is a compound of formula (IH):
  • compounds of the invention are of the formula (IH) or a pharmaceutically acceptable salt or solvate thereof wherein groups Z and R 1 to R 6 have any of the meanings as given hereinbefore.
  • compounds of the invention are of the formula (IH) and Z is -CH 2 O- or a pharmaceutically acceptable salt or solvate thereof wherein R 1 to R 6 have any of the meanings as given hereinbefore.
  • the compounds of the present invention may be in the form of their free base or physiologically acceptable salts thereof, particularly the monohydrochloride or monomesylate salts.
  • the present invention also provides a general process (A) for preparing compounds of formula (I) which process comprises: reacting a compound of fo
  • R 1 -R 6 represent R 1 to R 6 as hereinbefore defined or are groups that may be readily convertible to R 1 to R 6 .
  • This general method (A) can be conveniently performed by mixing the two components in a suitable solvent such as pyridine or dichloromethane (in the presence of a base), at 0°C.
  • a suitable solvent such as pyridine or dichloromethane (in the presence of a base), at 0°C.
  • the present invention also provides a general process (B) for preparing compounds of formula (I), which process comprises:
  • R r -R 6' represent R 1 to R 6 as hereinbefore defined or are groups that may be readily convertible to R 1 to R 6
  • V and W contain the appropriate functionalities to generate the Z linker.
  • the present invention also provides a general process (C) for preparing compounds of formula (I) which process comprises:
  • R 1' -R 6' represent R 1 to R 6 as hereinbefore defined or are groups that may be readily convertible to R 1 to R 6 , by substituting the group R 1 or the group R 3 using conventional techniques.
  • Interconversion of one of the R 1' to R 5' groups to the corresponding R 1 to R 5 groups typically arises when one compound of formula (I) is used as the immediate precursor of another compound of formula (I), or when it is easier to introduce a more complex or reactive substituent at the end of a synthetic sequence.
  • conversion of R 1' from a t-butoxycarbonyl (BOC) group to hydrogen is conducted by the treatment of the N-BOC protected compound with hydrogen chloride in ethanol or dioxan at room temperature.
  • Conversion of R 1' from hydrogen to an alkyl group is conducted by the treatment of the NH compound with the appropriate aldehyde in dichloroethane in the presence of a reducing agent, such as sodium triacetoxyborohydride, or by the treatment of the NH compound with the appropriate alkyl halide, such as iodomethane, under standard alkylation conditions (potassium carbonate in DMF at 60°C).
  • R 3' from hydrogen to an alkyl group is conducted by the treatment of the sulfonamide NH compound with the appropriate alcohol, such as methanol, under Mitsunobu conditions i.e. treatment with diisopropyl azodicarboxylate/triphenylphosphine and methanol in tetrahydrofuran at room temperature.
  • the appropriate alcohol such as methanol
  • compounds of formula (III) wherein Z represents CR 9 R 10 , R 4 -R 6 represent R 4 to R 6 as hereinbefore defined or are groups that may be readily convertible to R 4 to R 6 and R 9 and R 10 are as hereinbeforehand described, may be prepared from ortho, meta or para mercaptophenol (VI) by a novel 3 step process.
  • the present invention also provides a general process (D) for preparing compounds of formula (III) which process comprises:
  • base for example sodium hydride and an alkylating agent for example, a substituted benzyl bromide
  • Compounds of formula (IV) may be prepared from compounds of formula (II) by the treatment with the appropriate 4-substituted benzenesulfonyl chloride using standard conditions, for example in pyridine or dichloromethane in the presence of a base such as triethylamine at room temperature.
  • Compounds of formula (I) have been found to exhibit affinity for dopamine receptors, in particular the D3 and D2 receptors, and are useful in the treatment of disease states which require modulation of such receptors, such as psychotic conditions. Many of the compounds of formula (I) have also been found to have greater affinity for dopamine D3 than for D2 receptors.
  • the therapeutic effect of currently available antipsychotic agents is generally believed to be exerted via blockade of D2 receptors; however this mechanism is also thought to be responsible for undesirable extrapyramidal side effects (eps) associated with many neuroleptic agents. Without wishing to be bound by theory, it has been suggested that blockade of the dopamine D3 receptor may give rise to beneficial antipsychotic activity without significant eps.
  • Compounds of formula (I) may also exhibit affinity for other receptors not mentioned above, resulting in beneficial antipyschotic activity.
  • the compounds of formula (I) are of use as antipsychotic agents for example in the treatment of schizophrenia, schizo-affective disorders, schizophreniform diseases, psychotic depression, mania, acute mania, paranoid and delusional disorders. Furthermore, they may have utility as adjunct therapy in Parkinsons Disease, particularly with compounds such as L-DOPA and possibly dopaminergic agonists, to reduce the side effects experienced with these treatments on long term use (e.g. see Schwartz et al., Brain Res. Reviews, 1998, 26, 236-242).
  • D3 receptors D3 receptors
  • substance abuse examples include alcohol, cocaine, heroin and nicotine abuse.
  • Other conditions which may be treated by the compounds include dyskinetic disorders such as Parkinson's disease, neuroleptic- induced parkinsonism and tardive dyskinesias; depression; anxiety; agitation; tension; social or emotional withdrawal in psychotic patients; cognitive impairment including memory disorders such as Alzheimer's disease; psychotic states associated with neurodegenerative disorders, e.g.
  • Alzheimer's disease eating disorders; obesity; sexual dysfunction; sleep disorders; emesis; movement disorders; obsessive-compulsive disorders; amnesia; aggression; autism; vertigo; dementia; circadian rhythm disorders; and gastric motility disorders e.g. IBS.
  • the invention provides a compound of formula (I) as hereinbefore described or a pharmaceutically acceptable salt or solvate thereof for use in therapy.
  • the invention also provides a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof for use in the treatment of a condition which requires modulation of a dopamine receptor.
  • the invention also provides a compound of formula (I) as hereinbefore described or a pharmaceutically acceptable salt or solvate thereof for use in the treatment of psychotic disorders, schizophrenia, Parkinsons disease, substance abuse, dyskinetic disorders, depression, bipolar disorder, anxiety, cognitive impairment, eating disorders, obesity, sexual dysfunction, sleep disorders, emesis, movement disorders, obsessive-compulsive disorders, amnesia, aggression, autism, vertigo, dementia, circadian rhythm disorders and gastric motility disorders.
  • psychotic disorders schizophrenia, Parkinsons disease, substance abuse, dyskinetic disorders, depression, bipolar disorder, anxiety, cognitive impairment, eating disorders, obesity, sexual dysfunction, sleep disorders, emesis, movement disorders, obsessive-compulsive disorders, amnesia, aggression, autism, vertigo, dementia, circadian rhythm disorders and gastric motility disorders.
  • the invention also provides the use of a compound of formula (I) as hereinbefore described or a pharmaceutically acceptable salt or solvate thereof in the manufacture of a medicament for the treatment of a condition which requires modulation of a dopamine receptor.
  • the invention also provides the use of a compound of formula (I) as hereinbefore described or a pharmaceutically acceptable salt or solvate thereof in the manufacture of a medicament for the treatment of psychotic disorders, schizophrenia, Parkinsons disease, substance abuse, dyskinetic disorders, depression, bipolar disorder, anxiety, cognitive impairment, eating disorders, obesity, sexual dysfunction, sleep disorders, emesis, movement disorders, obsessive-compulsive disorders, amnesia, aggression, autism, vertigo, dementia, circadian rhythm disorders and gastric motility disorders.
  • psychotic disorders schizophrenia, Parkinsons disease, substance abuse, dyskinetic disorders, depression, bipolar disorder, anxiety, cognitive impairment, eating disorders, obesity, sexual dysfunction, sleep disorders, emesis, movement disorders, obsessive-compulsive disorders, amnesia, aggression, autism, vertigo, dementia, circadian rhythm disorders and gastric motility disorders.
  • the invention also provides a method of treating a condition which requires modulation of a dopamine receptor, which comprises administering to a mammal in need thereof an effective amount of a compound of formula (I) as hereinbefore described or a pharmaceutically acceptable salt or solvate thereof.
  • the invention provides a method of treating psychotic disorders, schizophrenia, Parkinsons disease, substance abuse, dyskinetic disorders, depression, bipolar disorder, anxiety, cognitive impairment, eating disorders, obesity, sexual dysfunction, sleep disorders, emesis, movement disorders, obsessive-compulsive disorders, amnesia, aggression, autism, vertigo, dementia, circadian rhythm disorders and gastric motility disorders which comprises administering to a mammal in need thereof an effective amount of a compound of formula (I) as hereinbefore described or a pharmaceutically acceptable salt or solvate thereof.
  • a preferred use for dopamine antagonists according to the present invention is in the treatment of psychotic disorders, schizophrenia, Parkinsons disease, substance abuse, dyskinetic disorders, depression, bipolar disorder, anxiety and cognitive impairment.
  • Treatment includes prophylaxis, where this is appropriate for the relevant condition(s).
  • the compounds according to the invention may advantageously be used in conjunction with one or more other therapeutic agents, for instance, different antidepressant agents such as 5HT 3 antagonists, serotonin agonists, NK-1 antagonists, selective serotonin reuptake inhibitors (SSRI), noradrenaline re-uptake inhibitors (SNRI), tricyclic antidepressants, dopaminergic antidepressants, H 3 antagonists, 5HT 1A antagonists, 5HT 1B antagonists, 5HT 1D antagonists, D-i agonists, M ⁇ agonists and/or anticonvulsant agents.
  • different antidepressant agents such as 5HT 3 antagonists, serotonin agonists, NK-1 antagonists, selective serotonin reuptake inhibitors (SSRI), noradrenaline re-uptake inhibitors (SNRI), tricyclic antidepressants, dopaminergic antidepressants, H 3 antagonists, 5HT 1A antagonists, 5HT 1B antagonists, 5HT 1D antagonists, D-
  • Suitable 5HT 3 antagonists which may be used in combination of the compounds of the inventions include for example ondansetron, granisetron, metoclopramide.
  • Suitable serotonin agonists which may be used in combination with the compounds of the invention include sumatriptan, rauwolscine, yohimbine, metoclopramide.
  • Suitable SSRIs which may be used in combination with the compounds of the invention include fluoxetine, citalopram, femoxetine, fluvoxamine, paroxetine, indalpine, sertraline, zimeldine.
  • Suitable SNRIs which may be used in combination with the compounds of the invention include venlafaxine and reboxetine.
  • Suitable tricyclic antidepressants which may be used in combination with a compound of the invention include imipramine, amitriptiline, chlomipramine and nortriptiline.
  • Suitable dopaminergic antidepressants which may be used in combination with a compound of the invention include bupropion and amineptine.
  • Suitable anticonvulsant agents which may be used in combination of the compounds of the inventions include for example divalproex, carbamazepine and diazepam.
  • the compounds of the combination or composition may be administered simultaneously (either in the same or different pharmaceutical formulations), separately or sequentially.
  • the compounds of the present invention are usually administered as a standard pharmaceutical composition.
  • the present invention therefore provides in a further aspect a pharmaceutical composition comprising a compound of formula (I) as hereinbefore described or a pharmaceutically (i.e. physiologically) acceptable salt thereof and a pharmaceutically (i.e. physiologically) acceptable carrier.
  • the pharmaceutical composition can be for use in the treatment of any of the conditions described herein.
  • the compounds of formula (I) may be administered by any convenient method, for example by oral, parenteral (e.g. intravenous), buccal, sublingual, nasal, rectal or transdermal administration and the pharmaceutical compositions adapted accordingly.
  • parenteral e.g. intravenous
  • buccal e.g. sublingual
  • nasal rectal
  • transdermal administration e.g. transdermal
  • the compounds of formula (I) as hereinbefore described and their pharmaceutically acceptable salts which are active when given orally can be formulated as liquids or solids, for example syrups, suspensions or emulsions, tablets, capsules and lozenges.
  • a liquid formulation will generally consist of a suspension or solution of the compound or pharmaceutically acceptable salt in a suitable liquid carrier(s) for example an aqueous solvent such as water, ethanol or glycerine, or a non-aqueous solvent, such as polyethylene glycol or an oil.
  • a suitable liquid carrier(s) for example an aqueous solvent such as water, ethanol or glycerine, or a non-aqueous solvent, such as polyethylene glycol or an oil.
  • the formulation may also contain a suspending agent, preservative, flavouring or colouring agent.
  • a composition in the form of a tablet can be prepared using any suitable pharmaceutical carrier(s) routinely used for preparing solid formulations.
  • suitable pharmaceutical carrier(s) include magnesium stearate, starch, lactose, sucrose and cellulose.
  • a composition in the form of a capsule can be prepared using routine encapsulation procedures.
  • pellets containing the active ingredient can be prepared using standard carriers and then filled into a hard gelatin capsule; alternatively, a dispersion or suspension can be prepared using any suitable pharmaceutical carrier(s), for example aqueous gums, celluloses, silicates or oils and the dispersion or suspension then filled into a soft gelatin capsule.
  • Typical parenteral compositions consist of a solution or suspension of the compound or pharmaceutically acceptable salt in a sterile aqueous carrier or parenterally acceptable oil, for example polyethylene glycol, polyvinyl pyrrolidone, lecithin, arachis oil or sesame oil.
  • a sterile aqueous carrier or parenterally acceptable oil for example polyethylene glycol, polyvinyl pyrrolidone, lecithin, arachis oil or sesame oil.
  • the solution can be lyophilised and then reconstituted with a suitable solvent just prior to administration.
  • compositions for nasal administration may conveniently be formulated as aerosols, drops, gels and powders.
  • Aerosol formulations typically comprise a solution or fine suspension of the active substance in a pharmaceutically acceptable aqueous or non-aqueous solvent and are usually presented in single or multidose quantities in sterile form in a sealed container, which can take the form of a cartridge or refill for use with an atomising device.
  • the sealed container may be a unitary dispensing device such as a single dose nasal inhaler or an aerosol dispenser fitted with a metering valve which is intended for disposal once the contents of the container have been exhausted.
  • the dosage form comprises an aerosol dispenser
  • a propellant which can be a compressed gas such as compressed air or an organic propellant such as a fluorochloro- hydrocarbon.
  • the aerosol dosage forms can also take the form of a pump-atomiser.
  • compositions suitable for buccal or sublingual administration include tablets, lozenges and pastilles, wherein the active ingredient is formulated with a carrier such as sugar and acacia, tragacanth, or gelatin and glycerin.
  • a carrier such as sugar and acacia, tragacanth, or gelatin and glycerin.
  • compositions for rectal administration are conveniently in the form of suppositories containing a conventional suppository base such as cocoa butter.
  • compositions suitable for transdermal administration include ointments, gels and patches.
  • the composition is in unit dose form such as a tablet, capsule or ampoule.
  • Each dosage unit for oral administration contains preferably from 1 to 250 mg (and for parenteral administration contains preferably from 0.1 to 25 mg) of a compound of the formula (I) or a pharmaceutically acceptable salt thereof calculated as the free base.
  • the pharmaceutically acceptable compounds of the invention will normally be administered in a daily dosage regimen (for an adult patient) of, for example, an oral dose of between 1 mg and 500 mg, preferably between 10 mg and 400 mg, e.g. between 10 and 250 mg or an intravenous, subcutaneous, or intramuscular dose of between 0.1 mg and 100 mg, preferably between 0.1 mg and 50 mg, e.g. between 1 and 25 mg of the compound of the formula (I) or a pharmaceutically acceptable salt thereof calculated as the free base, the compound being administered 1 to 4 times per day.
  • the compounds will be administered for a period of continuous therapy, for example for a week or more.
  • the ability of the compounds to bind selectively to human D2/D3 dopamine receptors can be demonstrated by measuring their binding to cloned receptors.
  • the inhibition constants (K j ) of test compounds for displacement of [ " ⁇ Sij-.iodosuiprjde binding to human D2/D3 receptors expressed in CHO cells were determined as follows. The cell lines were shown to be free from bacterial, fungal and mycoplasmal contaminants, and stocks of each were stored frozen in liquid nitrogen. Cultures were grown as monolayers or in suspension in standard cell culture media.
  • Cells were recovered by scraping (from monolayers) or by centrifugation (from suspension cultures), and were washed two or three times by suspension in phosphate buffered saline followed by collection by centrifugation. Cell pellets were stored frozen at -80°C. Crude cell membranes were prepared by homogenisation followed by high-speed centrifugation, and characterisation of cloned receptors achieved by radioligand binding.
  • CHO cell membranes Preparation of CHO cell membranes: Cell pellets were gently thawed at room temperature, and resuspended in about 20 volumes of ice-cold Extraction buffer; 5mM EDTA, 50mM Trizma pre-set crystals (pH7.4@37°C), 1mM MgCl2, 5mM KCl and 120mM NaCI. The suspension was homogenised using an Ultra-Turrax at full speed for 15 seconds. The homogenate was centrifuged at 18,000 r.p.m. for 15 min at 4°C in a Sorvall RC5C centrifuge. Supernatant was discarded, and homogenate re-suspended in extraction buffer then centrifugation was repeated.
  • the protein content was determined using a BCA protocol and bovine serum albumin as a standard (Smith, P. K., et al., Measurement of protein using bicinchoninic acid. Anal. Biochem. 150, 76-85 (1985)).
  • Binding experiments Crude D2/D3 cell membranes were incubated with 0.03nM [ ⁇ ]- lodosulpride (-2000 Ci/mmol; Amersham, U. K., and the test compound in a buffer containing 50mM Trizma pre-set crystals (pH 7.4 @ 37°C), 120mM NaCI, 5mM KCl, 2mM CaCl2, 1mM MgCl2, 0.3% (w/v) bovine serum albumin. The total volume is 0.2ml and incubated in a water bath at 37°C for 40 minutes.
  • the exemplified compounds have pK j values within the range of 6.0 - 9.2 at the dopamine D 3 receptor.
  • the exemplified compounds have pKj values within the range of 5.6 -8.0 at the dopamine D 2 receptor.
  • the exemplified compounds have pKj values within the range of 6.9 - 9.4 at the serotonin 5-HT 6 receptor.
  • the exemplified compounds have pKj values within the range of 7.1- 8.3 at the serotonin 5-HT 2C and 5-HT 2A receptor.
  • the aniline D1 (5 g, 19 mmol) was dissolved in dry CH 3 CN (100ml) and the solution was cooled to -15 °C.
  • Nitration of D4a was carried out by adding 70% aqueous nitric acid (8 g) dissolved in glacial acetic acid (100 mL)/acetic anhydride (10 mL) to the phenol D4a (20 g) dissolved in AcOH (200 mL)/acetic anhydride (20 mL) at 0°C. Aqueous work-up followed by chromatography on silica gel using 0-20% EtOAc/n-hexane as eluant afforded the title compound (11 g).
  • the title compound was prepared from 4-chlorobenzyl phenyl ether and sulfuryl chloride using a procedure similar to that for D9.
  • Nitration of D16a was carried out by adding 70% aqueous nitric acid (8 g) dissolved in glacial acetic acid (100 ml)/acetic anhydride (10 ml) to the phenol D15a (20 g) dissolved in AcOH (200 ml)/acetic anhydride (20 ml) at 0°C. Aqueous work-up followed by chromatography on silica gel using 0-20% EtOAc/n-hexane as eluant afforded the title compound D16b (11 g).
  • Examples 3-70 were prepared using analogous procedures to Examples 1 and 2 using the anilines D1 - D9, D15 or D16 and the appropriate sulfonyl chloride D11 , D12, D13 or D14. Products were isolated as either the free bases or hydrochloride salts. All 1 H NMR are consistent with the structures shown.
  • Examples 72-82 were prepared using analogous procedures to Example 71 and Descriptions 23-26 using the appropriately 8-substituted benzazepine. Products were isolated as either the free bases or hydrochloride salts. All 1 H NMR are consistent with the structures shown.
  • Examples 84-87 were prepared using analogous procedures to Example 83 using the anilines D20 and the appropriate benzaldehyde. Products were isolated as either the free bases or hydrochloride salts. All 1 H NMR are consistent with the structures shown.
  • Examples 90-91 were prepared using analogous procedures to Examples 89 and Description 22, using the appropriate aniline. Products were isolated as either the free bases or hydrochloride salts. All 1 H NMR are consistent with the structures shown.
  • Examples 93-94 were prepared using an analogous procedure to Example 92. Products were isolated as either the free bases or hydrochloride salts. All 1 H NMR are consistent with the structures shown.
  • Examples 96-97 were prepared using an analogous procedure to Example 95 using the appropriate sulfonyl chloride. Products were isolated as either the free bases or hydrochloride salts. All 1 H NMR are consistent with the structures shown.
  • Example 99 was prepared using an analogous procedure to Example 98. Product was isolated as either the free base or hydrochloride salt. All 1 H NMR are consistent with the structures shown.
  • Example 100
  • R 4 is phenyl
  • R and R 6 are hydrogen and R is a substituent on R 4

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
PCT/GB2003/001983 2002-05-10 2003-05-09 Dopamine receptor modulators as antipsychotic agents Ceased WO2003095428A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2003227919A AU2003227919A1 (en) 2002-05-10 2003-05-09 Dopamine receptor modulators as antipsychotic agents
EP03725384A EP1503989A1 (en) 2002-05-10 2003-05-09 Dopamine receptor modulators as antipsychotic agents
US10/513,919 US20070043026A1 (en) 2002-05-10 2003-05-09 Dopamine receptor modulators as antipsychotic agents
JP2004503446A JP2005532318A (ja) 2002-05-10 2003-05-09 抗精神病薬としてのドーパミン受容体モジュレーター

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0210762.1 2002-05-10
GBGB0210762.1A GB0210762D0 (en) 2002-05-10 2002-05-10 Compounds

Publications (1)

Publication Number Publication Date
WO2003095428A1 true WO2003095428A1 (en) 2003-11-20

Family

ID=9936447

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2003/001983 Ceased WO2003095428A1 (en) 2002-05-10 2003-05-09 Dopamine receptor modulators as antipsychotic agents

Country Status (6)

Country Link
US (1) US20070043026A1 (cg-RX-API-DMAC7.html)
EP (1) EP1503989A1 (cg-RX-API-DMAC7.html)
JP (1) JP2005532318A (cg-RX-API-DMAC7.html)
AU (1) AU2003227919A1 (cg-RX-API-DMAC7.html)
GB (1) GB0210762D0 (cg-RX-API-DMAC7.html)
WO (1) WO2003095428A1 (cg-RX-API-DMAC7.html)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005058328A1 (en) * 2003-12-18 2005-06-30 Abbott Gmbh & Co. Kg Tetrahydrobenzazepines and their use in the modulation of the dopamine d3 receptor
WO2005058837A1 (en) * 2003-12-17 2005-06-30 Glaxo Group Limited Benzazepine derivatives as histamine h3 antagonists
WO2006040179A1 (en) * 2004-10-14 2006-04-20 Abbott Gmbh & Co. Kg Aminoethylaromatic compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor
EP1837332A1 (en) * 2006-03-23 2007-09-26 Laboratorios Del Dr. Esteve, S.A. Substituted tetrahydroisoquinoline compounds, their preparation and use in medicaments
JP2008502644A (ja) * 2004-06-18 2008-01-31 グラクソ グループ リミテッド ヒスタミンh3アンタゴニストとしての3−シクロアルキルベンズアゼピン
US7504392B2 (en) 2002-05-29 2009-03-17 Glaxo Group Limited 2,3,4,5-tetrahydro-1H-3-benzazepines and their medical use
US7897595B2 (en) 2006-05-26 2011-03-01 Forest Laboratories Holdings Limited Pyridoazepine derivatives
JP2011516592A (ja) * 2008-04-16 2011-05-26 エフ.ホフマン−ラ ロシュ アーゲー ピリダジノングルコキナーゼアクチベーター
EP2332543A1 (en) * 2003-12-18 2011-06-15 Abbott GmbH & Co. KG Tetrahydrobenzazepines and their use in the modulation of the dopamine D3 receptor

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997048683A1 (en) * 1996-06-17 1997-12-24 Smithkline Beecham Plc Substituted benzamide derivatives and their use as anticonvulsants
WO1998041508A1 (en) * 1997-03-18 1998-09-24 Smithkline Beecham Plc Substituted isoquinoline derivatives and their use as anticonvulsants
WO1999021836A1 (en) * 1997-10-24 1999-05-06 Smithkline Beecham Plc Substituted isoquinoline derivatives and their use as anticonvulsants
DE10053799A1 (de) * 2000-10-30 2002-05-08 Bayer Ag Verwendung von Tetrahydroisochinolinsulfonamiden

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4321254A (en) * 1980-09-26 1982-03-23 Smithkline Corporation Antiallergic imidodisulfamides
US5112824A (en) * 1989-12-08 1992-05-12 Merck & Co., Inc. Benzofuran compounds as class III antiarrhythmic agents
US5684195A (en) * 1994-07-14 1997-11-04 G. D. Searle & Co. Method of preparing sulfmonamides from sulfones

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997048683A1 (en) * 1996-06-17 1997-12-24 Smithkline Beecham Plc Substituted benzamide derivatives and their use as anticonvulsants
WO1998041508A1 (en) * 1997-03-18 1998-09-24 Smithkline Beecham Plc Substituted isoquinoline derivatives and their use as anticonvulsants
WO1999021836A1 (en) * 1997-10-24 1999-05-06 Smithkline Beecham Plc Substituted isoquinoline derivatives and their use as anticonvulsants
DE10053799A1 (de) * 2000-10-30 2002-05-08 Bayer Ag Verwendung von Tetrahydroisochinolinsulfonamiden

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7504392B2 (en) 2002-05-29 2009-03-17 Glaxo Group Limited 2,3,4,5-tetrahydro-1H-3-benzazepines and their medical use
WO2005058837A1 (en) * 2003-12-17 2005-06-30 Glaxo Group Limited Benzazepine derivatives as histamine h3 antagonists
WO2005058328A1 (en) * 2003-12-18 2005-06-30 Abbott Gmbh & Co. Kg Tetrahydrobenzazepines and their use in the modulation of the dopamine d3 receptor
US8207160B2 (en) 2003-12-18 2012-06-26 Abbott Gmbh & Co. Kg Tetrahydrobenzazepines and their use in he modulation of the dopamine D3 receptor
JP2007514696A (ja) * 2003-12-18 2007-06-07 アボット ゲーエムベーハー ウント カンパニー カーゲー テトラヒドロベンズアゼピンおよびドーパミンd3レセプターの調節におけるこれらの使用
EP2332543A1 (en) * 2003-12-18 2011-06-15 Abbott GmbH & Co. KG Tetrahydrobenzazepines and their use in the modulation of the dopamine D3 receptor
JP2008502644A (ja) * 2004-06-18 2008-01-31 グラクソ グループ リミテッド ヒスタミンh3アンタゴニストとしての3−シクロアルキルベンズアゼピン
EP2371814A1 (en) * 2004-10-14 2011-10-05 Abbott GmbH & Co. KG Aminoethylaromatic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor
WO2006040179A1 (en) * 2004-10-14 2006-04-20 Abbott Gmbh & Co. Kg Aminoethylaromatic compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor
US8232426B2 (en) 2004-10-14 2012-07-31 Abbott Gmbh & Co. Kg Aminoethylaromatic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor
WO2007107373A1 (en) 2006-03-23 2007-09-27 Laboratorios Del Dr. Esteve S.A. Substituted tetrahydroisoquinoline compounds, their preparation and use in medicaments
EP1837332A1 (en) * 2006-03-23 2007-09-26 Laboratorios Del Dr. Esteve, S.A. Substituted tetrahydroisoquinoline compounds, their preparation and use in medicaments
US7897595B2 (en) 2006-05-26 2011-03-01 Forest Laboratories Holdings Limited Pyridoazepine derivatives
JP2011516592A (ja) * 2008-04-16 2011-05-26 エフ.ホフマン−ラ ロシュ アーゲー ピリダジノングルコキナーゼアクチベーター

Also Published As

Publication number Publication date
JP2005532318A (ja) 2005-10-27
AU2003227919A1 (en) 2003-11-11
US20070043026A1 (en) 2007-02-22
EP1503989A1 (en) 2005-02-09
GB0210762D0 (en) 2002-06-19

Similar Documents

Publication Publication Date Title
US20080269197A1 (en) Aromatic sulfones and their medical use
US20050176759A1 (en) 7-sulfonyl-3-benzazepine derivatives as modulators of the dopamine receptor and their use for the treatment cns disorders
WO2003068752A1 (en) Benzenesulfonamide derivatives as antipsychotic agents
EP1503989A1 (en) Dopamine receptor modulators as antipsychotic agents
US20050085461A1 (en) Benzenesulfonamide derivatives
EP1549639B1 (en) Sulphonamide derivatives as antipsychotic agents
EP1509504A1 (en) 7-phenylsulfonyl-tetrahydro-3-benzazepine derivatives as antipsychotic agents
ZA200409417B (en) Compounds.
US20070093473A1 (en) 7-Heteroarylsulfonyl-tetrahydro-3-benzazepine derivatives as antipsychotic agents
ZA200405804B (en) Benzenesulfonamide derivatives as antipsychotic agents
HK1075050B (en) Aromatic sulfones and their medical use

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004503446

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003725384

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003725384

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007043026

Country of ref document: US

Ref document number: 10513919

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 2003725384

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 10513919

Country of ref document: US